Quarterly report
Open the filing on sec.gov
Agenus Inc. (AGEN)
Nasdaq: AGEN · Biological Products, (No Diagnostic Substances) · Lexington, MA · filing with the SEC since 1999
The companyfiscal 2025, as filed
Revenue$114M+10.4%
Net income-$101,000+100.0%
Earnings per share$0.00+100.0%
Operating cash flow-$77.2M+51.2%
Cash$3.0M-92.6%
Debt$0.00-100.0%
Shareholders’ equity-$271M+16.9%
Shares, diluted29.7M+38.5%
Return on equityn/a
The recordfrom its filings
Filings in 202676
Newest filingNov 5 · 10-Q
Annual reportMar 16, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted66
Filer categoryAccelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $134MNet income $29.5MCash from operations -$104Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.